viz.ai, Companies involved in AI-supported imaging and care coordination are working with Pharma Giant Novartis to develop their own AI-powered workflows within the Viz Oncology Suite.
viz.ai offers a care coordination platform with over 50 FDA-cleared algorithms that help analyse medical image data to support diagnosis, ease of workflow and treatment decisions.
The company will focus on improving “identifying and stratifying patients diagnosed with prostate and breast cancer based on key risk factors, and promoting access to guidelines-based precision therapy.”
The collaboration also aims to address delays in diagnosis and treatment by utilizing AI to ensure patients are identified and treated faster with timely, coordinated care.
viz.ai plans to develop two new AI-powered products. That is, it is designed to identify eligible patients for guidelines-based treatment with referral to the relevant expert. That is, it is a supply that supports breast oncologists by automating patient reviews, aggregating risk-related data, introducing treatment guidelines, and promoting collaboration with the Multi-Diplina team.
“We are excited to partner with Novartis, a leader in innovative pharmaceutical and oncology, to accelerate access to timely, guidelines-based care for patients facing prostate cancer,” Dr. Chris Mansi, CEO and co-founder of viz.ai, said in a statement.
“This collaboration is part of a broader strategic expansion into oncology and promotes Viz.ai’s mission to fundamentally transform healthcare through intelligent care coordination.”
Bigger trends
In May, viz.ai joined forces Biotechnology Company Regeneron and Biopharmaceutical Company Sanofi will deploy and research AI-enabled workflow tools for COPD.
Through the partnership, Sanofi and Regeneron will support the investigation of the Viz COPD module, which utilizes AI and electronic health record data to identify and manage high-risk COPD patients.
In 2023, I signed viz.ai The multi-year agreement with Bristol-Myers Squibb will release AI-enabled algorithms and software for the provider workflow called Viz HCM.
Viz HCM is used to identify and evaluate patients with hypertrophic cardiomyopathy by reviewing routine electrocardiograms and identifying suspected cases for clinical review. Integrated into viz.ai’s cardio suite product.
2023, Dawn Health has entered into a strategic partnership with Novartis to develop a chronic condition management platform.
Under the collaboration, Dawn and Novartis have built remote monitoring and management tools for chronic diseases with unmet needs and concerns regarding the progression of diseases such as multiple sclerosis, hypertension, cardiovascular disease, and breast cancer.
The platform includes patient mobile apps, symptom monitoring, digital biomarkers, clinical decision support services, and virtual clinic products tailored to your specific disease and condition.
2022, Anumana, a joint venture of EHR data company Mayo Clinic, has joined a strategic partnership with Novartis to develop artificial intelligence tools for the detection of cardiovascular disease.
This collaboration focuses on deploying AI algorithms that analyze ECGs to find left ventricular dysfunction, which could lead to heart failure and atherosclerotic cardiovascular disease.
